Abera Bioscience

Abera Bioscience P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Abera Bioscience (ABERA.SL) as of Oct 15, 2026 is -32.44. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -89.93 — a change of -63.93% (higher).

P/FCF

-32.44

YoY

-63.93%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Abera Bioscience is 2025 -32.44 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Abera Bioscience was 2024 -89.93 . It decreases by -63.93% higher compared to the previous year.

The Abera Bioscience P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2019
-39.97 SEK
Jan 1, 2020
-43.48 SEK
Jan 1, 2022
-6.07 SEK
Jan 1, 2023
-6.75 SEK
Jan 1, 2024
-89.93 SEK
Jan 1, 2025
-32.44 SEK
The Abera Bioscience P/FCF history
YEARP/FCFYoY
-32.44-63.93%
-89.93+1,232.66%
-6.75+11.19%
-6.07-86.04%
-43.48+8.77%
-39.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Abera Bioscience Stock analysis

What does Abera Bioscience do? Abera Bioscience AB is a biotechnology company based in Uppsala, Sweden, operating within the healthcare sector. The company focuses on the research and development of pharmaceutical products, particularly in the field of vaccine development. It utilizes a proprietary vaccine delivery platform to advance vaccine candidates toward late pre-clinical or early clinical stages. Abera Bioscience aims to identify licensing partners for further development of its vaccine candidates. The company's technology is primarily applied in the development of vaccines targeting pneumococci and immunooncology. Abera Bioscience has a small operational footprint, employing five full-time staff members. It completed its initial public offering (IPO) on February 24, 2021, and is listed under the ticker ABERA.SL with ISIN SE0015245097. The company's headquarters are located in Uppsala, and it operates primarily within the Nordic market. Its website is https://aberabio.com/. The company's activities are centered on advancing vaccine candidates through its platform technology, with an emphasis on strategic partnerships for subsequent development phases. Abera Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Abera Bioscience stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Abera Bioscience is -32.44 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Abera Bioscience changed from -89.93 to -32.44, representing a -63.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Abera Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Abera Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Abera Bioscience

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Abera Bioscience